Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients

Table 2 Propensity-score matching of statin-treated with non statin-treated patients

	Statin group (n = 157)	Non-statin group (n = 157)	Effect size	Values (95% CI)	P value
Diabetes	117 (75.1)	83 (53.0)	Odds ratio	2.67 (1.60 to 4.45)	0.0002
Patients on antidiabetic drugs	110 (70.5)	67 (42.9)	Odds ratio	3.18 (1.96 to 5.15)	< 0.0001
Patients with number of antidiabetic drugs
0	46 (29.5)	89 (57.1)	Common odds ratio	2.88 (1.83 to 4.53)	< 0.0001
1	39 (24.7)	27 (17.0)
2	26 (17.0)	18 (11.6)
> 2	45 (28.8)	22 (14.3)
Patients on insulin treatment	42 (26.8)	23 (14.4)	Odds ratio	2.17 (1.25 to 3.74)	0.006
Fasting blood glucose [mmol/L]	7.1 (5.9 to 10.1)	6.0 (5.4 to 8.0)	Mean difference^a	0.14 (0.06 to 0.22)	0.0002
2 h blood glucose [mmol/L]	11.6 (7.4 to 17.0)	9.0 (6.6 to 13.8)	Mean difference^a	0.18 (0.06 to 0.29)	0.002
HbA1c [%]	6.8 (6.0 to 8.2)	6.2 (5.7 to 7.1)	Mean difference^a	0.09 (0.04 to 0.14)	0.0001

The comparison of the main patient characteristics between statin and non-statin treatment groups after propensity score-matching and multiple imputation is shown. Values are presented as n (%) or median (IQR) unless otherwise indicated. ^acalculated on log-transformed data. Abbreviations: HbA1c hemoglobin A1c

ISSN: 1755-8794